Arrowhead Pharmaceuticals
Open
$74.27
Prev. Close
$74.33
High
$74.56
Low
$74.27
Market Snapshot
$10.44B
-34.7
-5.16
$2.5M
711
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 711 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 711 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Recently from Cashu
Arrowhead Pharmaceuticals Advances RNAi Therapies for Serious Metabolic and Genetic Diseases
Arrowhead Pharmaceuticals (Ticker: ARWR) is making significant strides in the development of treatments for serious metabolic and genetic diseases. During recent discussions, Chief Medical Officer Jam…
Arrowhead Pharmaceuticals Advances siRNA Therapeutics Amid Clinical Trials and Market Challenges
Arrowhead Pharmaceuticals (Ticker: ARWR) recently emphasizes its commitment to advancing siRNA therapeutics, highlighted by key developments shared during a recent Jefferies fireside chat. Chief Medic…
Arrowhead Pharmaceuticals Enters Licensing Agreement with Madrigal for Liver Disease Therapy Development
Arrowhead Pharmaceuticals (Ticker: ARWR) announces an exclusive licensing agreement with Madrigal Pharmaceuticals for the development of a therapeutic targeting metabolic dysfunction-associated steato…
Arrowhead Pharmaceuticals Advances RNA Interference Pipeline with Promising FCS Treatment Launch
Arrowhead Pharmaceuticals (Ticker: ARWR) is at a pivotal moment as it transitions into a commercial phase while focusing on expanding its RNA interference pipeline. At the recent BofA Annual Healthcar…